Unusual volume scanner: high RVOL stocks today
Volume precedes price. Before a stock breaks out, before the news wire prints, before the chat-room alert fires, volume is moving. Relative volume is the metric that surfaces it.
Leader right now: DCOY +38.70% at $3.53. Sourced from the live 15-min-delayed scanner snapshot above.
// As of September 22, 2026 · delayed 15 min
What's moving the tape on DCOY, grounded in Tapeboard's data. Not investment advice.
As of
- Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline — Benzinga - Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference — Yahoo
- The company is exploring non-dilutive federal grants and public health collaborations to support its biodefense pipeline. - The recent news suggests that the company is actively seeking partnerships and funding to advance its research.
- The company has a history of significant losses, with a net income of -$12518480 in 2025 and -$5575777 in 2024. - The company's operating expenses have been increasing, with $12613952 in 2025 and $5734316 in 2024.
- The company has a high short interest ratio, with a squeeze score of 9.9 and 0.49 days to cover. - The company's revenue and gross margin are not available in the data.
- The company's future revenue and profitability are uncertain due to the lack of available data. - The company's ability to secure non-dilutive federal grants and public health collaborations is not guaranteed. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on CORO, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data. - Price is up +0.79% on extremely high relative volume (RVOL 190.79x).
- Trading near the top of its 52‑week range (97% of the high‑low span). - Dividend yield of ~2.1% provides income while the ETF shows upward momentum.
- Price is just below the 52‑week high, leaving little room for further upside before a potential pull‑back. - The ETF’s fundamentals show zero earnings (EPS TTM = 0) and no P/E, limiting traditional valuation support.
- Shares are not easy to borrow (easyToBorrow: false), which could constrain short‑selling and increase borrowing costs. - No analyst estimates or earnings surprises are provided, indicating limited external guidance.
- Market‑cap, shares outstanding, and float are not disclosed, obscuring size and liquidity context. - No news or analyst data means we lack insight into catalysts or sentiment driving the move. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on VKTX, grounded in Tapeboard's data. Not investment advice.
As of
- "Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing" (Benzinga) - "Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735… 22% Placebo-Adjusted Weight Loss Reported At Week 33" (Benzinga)
- Strong analyst consensus: 9 strong buys, 14 buys across multiple future periods. - High RVOL (28.96x) and day volume 33.2M indicate intense buying interest.
- Recent SeekingAlpha headline: "The Market Might Shrug Off The Maintenance Data" suggests skepticism. - Negative earnings: net income -$0.36B FY2025, EPS -3.19, PE -8.33.
- Squeeze score 34.8/100 (moderate) and days to cover 12.6 signal potential short‑squeeze volatility. - No revenue (SEC shows $0) and continued cash‑flow burn (-$278.7M operating FY2025).
- Exact timing and magnitude of future VK2735 regulatory milestones are not disclosed. - Future dilution risk from potential financing needs given ongoing losses. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on DNN, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price up $0.03 (+1.03%) on elevated volume (9.07M shares, RVOL 6.07x)
- Strong intraday buying pressure shown by high RVOL and price above the 52‑week low - Short interest days‑to‑cover at 3.5 suggests limited immediate downside pressure
- Fundamentals remain weak: negative EPS (-0.18) and a very high P/S ratio (>900) - Easy‑to‑borrow flag is false, indicating potential borrowing constraints for shorts
- Stock sits on the FINRA threshold list (squeeze score 26.6/100) - Easy‑to‑borrow is false, which could increase volatility if short covering occurs
- No recent news or catalyst data to explain the volume spike - Current short‑interest percentage of float is not provided (si_pct_float: null) --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on INOD, grounded in Tapeboard's data. Not investment advice.
As of
- "Cerebras Systems vs. Innodata: Which AI-Driven Tech Stock Is a Better Buy in 2026?" — Yahoo - "Innodata's Customer Diversification Effort: Is It Finally Paying Off?" — Yahoo
- Revenue up 47.6% YoY with Q2 2026 EPS surprise of +89.6% and Q1 surprise of +446.9% - Analyst consensus shows 9 strong buys/buys vs 1 hold across multiple 2026 periods
- Stock still down ~47% over the last 3 months per recent headline - P/E ratio ~53 and P/S ~7.6 indicate premium valuation relative to peers
- Short interest days to cover 3.1 with easyToBorrow flag false, suggesting borrowing constraints - Squeeze score low at 19.7/100, limiting short‑squeeze potential
- No clear forward guidance on FY 2027 revenue or margin expansion - Uncertain impact of new board appointment (Admiral Rogers) on federal contract pipeline --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on WBD, grounded in Tapeboard's data. Not investment advice.
As of
- Warner Bros. Discovery (WBD) Surges 10.8%: Is This an Indication of Further Gains? — Yahoo - Warner Bros. Discovery: Closing A Merger Can Be A Real Challenge — SeekingAlpha - Warner Bros. Discovery (WBD) Signs Multi Year Harry Potter Gaming Accessories Deal — Yahoo - Why Did AMD, WBD, MRNA Stocks Surge To 52-Week Highs Today? — Yahoo
- Recent news suggests that Warner Bros. Discovery is making progress on its merger with Paramount, which could lead to further gains. - The company has also signed a multi-year licensing deal with PowerA to produce Harry Potter-themed gaming accessories, which could expand its consumer products reach.
- The company's revenue has declined by 5.1% year-over-year, which could be a concern for investors. - The company's operating expenses have increased, which could put pressure on its profitability.
- The company's short interest is relatively high, with a squeeze score of 9 and 3.4 days to cover. - The company's float is large, with 2.385 billion shares outstanding.
- The company's future prospects are uncertain, and it is difficult to predict how the merger with Paramount will affect its stock price. - The company's ability to execute on its strategy and manage its expenses will be critical to its future success. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on BFLY, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price up 17.38% on heavy volume (RVOL 4.37x) vs prior close $8.14
- Revenue grew +19% YoY to $0.10B with improving gross margin 46.9% - Analyst estimates consistently show strong buy/buy consensus across multiple periods
- Net income remains negative ($-0.08B) and EPS is negative (-0.31) - Operating cash flow negative (-$12.7M) and free cash flow negative (-$16.0M)
- High price-to-sales ratio (22.5) suggests rich valuation relative to sales - Short interest data limited; easyToBorrow flag is false, indicating potential borrowing constraints
- No forward guidance or upcoming catalysts disclosed in the provided data - Lack of recent news leaves uncertainty about any near‑term operational developments --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on GTBIF, grounded in Tapeboard's data. Not investment advice.
As of
- Price up $0.28 (+3.83%) on heavy volume with RVOL 9.59x vs average. - Recent news: “Green Thumb Industries Announces $50 Million Share Repurchase Program” (Yahoo) and “Wall Street Analysts See a 103.26% Upside in Green Thumb Industries Inc. (GTBIF)” (Yahoo).
- Share repurchase program signals confidence and could support price via reduced supply. - Strong earnings surprises: Q1 2026 EPS beat estimate by 1,047%; Q4 2025 beat by 2,473%.
- Cannabis sector remains sensitive to regulatory shifts and banking restrictions. - High RVOL suggests speculative trading that may not be sustained by fundamentals.
- No short‑interest data provided, limiting insight into bearish pressure. - Elevated trading volume (RVOL 9.59x) can increase volatility and price swings.
- Timeline and impact of potential federal cannabis reform remain unclear. - Execution of the $50 M buyback and its effect on float are not yet disclosed. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on OMER, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price up $1.65 (+8.9%) on volume 1.05M, RVOL 2.47x indicating heightened activity
- Shares trading above 52‑week high ($19.65) showing strong upward momentum - Short interest modest (days to cover 5.5, squeeze score 28.9) limiting downside pressure
- FY 2025 net loss of $3.35M and negative EPS (-$0.05) reflect ongoing unprofitability - Negative book value per share (-$0.71) and PB ratio -28.3 signal balance‑sheet weakness
- Operating cash flow negative for FY 2025 (-$116M) and FY 2024 (-$149M) - Easy‑to‑borrow flag false, suggesting potential borrowing constraints for shorts
- No forward guidance or pipeline updates provided in the data - Unclear timing of any potential catalysts driving the current price move --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on UNG, grounded in Tapeboard's data. Not investment advice.
As of
- Price rose 5.7% to $10.845 on heavy trading (44 M shares, RVOL 2.73×) indicating strong short‑term buying pressure. - No recent news available in the data to explain the move beyond price/volume action.
- The fund reported $34.2 M net income for FY 2025 and holds $438 M cash with modest liabilities ($28.8 M). - Operating cash flow was positive $127 M in the latest fiscal year, showing underlying cash generation.
- TTM EPS is –71.46 and recent quarterly revenues have swung sharply negative (e.g., –$121 M in Q2 2025). - The fund’s price remains well below its 52‑week high ($17.02), suggesting limited upside momentum.
- Shares are shortable but not easy to borrow, which could constrain short‑selling and increase volatility. - The fund’s net income shows large quarter‑to‑quarter swings, exposing investors to earnings volatility. UNKNOWS - Future natural‑gas price trends and demand shifts that drive the fund’s performance are not detailed in the data. - Any upcoming regulatory or macro‑economic events affecting energy markets are unknown from the provided information. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on GRAB, grounded in Tapeboard's data. Not investment advice.
As of
- "Why Is Grab Stock Trading Higher Today?" highlights CEO and COO insider purchases of ~10.65 M shares worth >$30.7 M. - "Grab to Buy 60% of Atome for $1.49B, Raises 2028 Growth Targets" announces a controlling stake in Atome Financial and lifted long‑term guidance.
- Analyst estimates show strong consensus: 10 Strong Buy, 17 Buy, 2 Hold across multiple periods. - Recent earnings surprises were large (+157.5% Q2 2026, +88.7% Q1 2026) and the company completed a share‑repurchase plan.
- The stock sits near the bottom of its 52‑week range (12% of the range) with a high P/S of 3.49, suggesting stretched valuation. - Squeeze score is modest (33.8/100) and days to cover short interest are 6.8, limiting short‑squeeze potential.
- Short interest is 261.65M shares (≈8.7% of float) and the stock is not easy to borrow (easyToBorrow: false). - RVOL is elevated at 3.36×, indicating unusually high trading activity that could reverse quickly.
- How the Atome acquisition will integrate and impact profitability remains unclear. - Broader macro‑economic conditions in Southeast Asia and consumer‑spending trends are not detailed in the data. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on XLF, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price down $0.99 (-1.77%) on volume 44.1M shares, RVOL 1.67x indicating above‑average activity
- Dividend yield of ~1.5% provides income while price sits 68% through its 52‑week range - ETF holds broad financial‑sector exposure, which could benefit from a stabilizing interest‑rate environment
- ETF shows negative price momentum today, reflecting broader market pressure on financials - No earnings or analyst estimates are available, limiting forward‑looking visibility
- Sector sensitivity to rate changes and credit conditions could amplify volatility - Large daily volume suggests heightened trader interest, which may lead to sharp swings
- Future Federal Reserve policy direction and its impact on bank profitability - Any upcoming regulatory developments affecting the financial industry that aren’t captured in the data set --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
See this live in the Tapeboard scanner
This table is baked at build time and never moves. The scanner runs the same scan continuously, streaming and filterable, with a chart and research pane one click away on every row. Free, no account needed.
Open the live unusual-volume scannerWhat are the biggest unusual-volume movers today?
- // RVOL above 2x the 10-day average for the same time of day
- // Sorted by RVOL descending so the biggest anomalies surface first
- // Optional price floor to exclude illiquid sub-$1 names
- // Optional gap and float filters layered on top
- // Click-through to time and sales, Level 2 book, and recent filings
- // Streaming real-time. Rows update as prints land, not on a 10-second refresh delay.
- // Click any ticker for the full research pane: chart, Level 2, time & sales, filings, insider activity, news recency.
- // 15-minute delay on the public surface; signed-in users see the live tape without delay.
- // Free to view. No card. No paywall on this page.
// Other movers categories you might want next to this one:
Watch the movers live on Tapeboard.
// 28 sec to first scanner · no card · cancel anytime
Start free View pricing See it live in the scanner